{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:51Z","timestamp":1787070891985,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Patients undergoing cancer treatment as well as cancer survivors commonly describe behavioral alterations. As a matter of fact, neuropsychiatric adverse events (NPAEs) have been extensively described with older immunotherapies, especially with interferon alfa. However, there are little data investigating the NPAEs of immune checkpoint inhibitors (ICIs). Therefore, the aim of this study is to evaluate the safety profile of ICI in terms of NPAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>This is a prospective, interventional, self-controlled study. Participants receiving ICIs as unique therapy, between February and December 2019, were evaluated at the beginning of their treatment protocol, at 1 month and finally at 3 months. During the three evaluations, disease and patients' characteristics were assessed, as well as NPAEs using the Brief Psychiatric Rating Scale (BPRS) questionnaire, the psychological stress due to cancer's burden using the Herth hope index, and the performance status (PS) using the Eastern Cooperative Oncology Group (ECOG) score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Forty-four patients were enrolled, of whom 24 patients completed their three evaluation visits. No changes in BPRS total score were found throughout the study period. However, two subscores of the BPRS, \u201cmotor retardation\u201d (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008) and \u201ctension\u201d or \u201cnervousness\u201d (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.002), increased starting the 1\n                      <jats:sup>st<\/jats:sup>\n                      month of treatment. Moreover, age (r = 0.426,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.038) and the baseline PS (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.027) were the main risk factors of such manifestations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      This study suggests that ICI could be responsible for motor retardation and increased tension starting the 1\n                      <jats:sup>st<\/jats:sup>\n                      month of treatment, with higher ECOG score and older age being the main risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1088_20","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T10:31:54Z","timestamp":1674815514000},"page":"140-146","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Increased psychomotor retardation and tension as short-term neuropsychiatric adverse events of immune checkpoint inhibitors: A prospective cohort study"],"prefix":"10.4103","volume":"18","author":[{"given":"Rami Bou","family":"Khalil","sequence":"first","affiliation":[{"name":"Hotel Dieu de France hospital, Beirut, Lebanon"},{"name":"Department of Psychiatry, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kassab","sequence":"additional","affiliation":[{"name":"Hotel Dieu de France hospital, Beirut, Lebanon"},{"name":"Department of Psychiatry, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Costa","sequence":"additional","affiliation":[{"name":"Hotel Dieu de France hospital, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady Gh","family":"Haddad","sequence":"additional","affiliation":[{"name":"Hotel Dieu de France hospital, Beirut, Lebanon"},{"name":"Department of Hematology and Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Richa","sequence":"additional","affiliation":[{"name":"Hotel Dieu de France hospital, Beirut, Lebanon"},{"name":"Department of Psychiatry, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kattan","sequence":"additional","affiliation":[{"name":"Hotel Dieu de France hospital, Beirut, Lebanon"},{"name":"Department of Hematology and Oncology, Faculty of Medicine, Saint Joseph University of Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"key":"R1-20250510","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2012.43.0116","article-title":"Cancer- and cancer treatment-associated cognitive change: An update on the state of the science","volume":"30","author":"Ahles","year":"2012","journal-title":"J Clin Oncol"},{"key":"R2-20250510","doi-asserted-by":"crossref","first-page":"5534","DOI":"10.1158\/1078-0432.CCR-08-2584","article-title":"Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer","volume":"15","author":"Bower","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R3-20250510","first-page":"283","article-title":"Physical and mental health among cancer survivors: Considerations for long-term care and quality of life","volume":"75","author":"Naughton","year":"2014","journal-title":"N C Med J"},{"key":"R4-20250510","first-page":"112","article-title":"Chemobrain","volume":"20","author":"Szentmartoni","year":"2018","journal-title":"Neuropsychopharmacol Hung"},{"key":"R5-20250510","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.pharmthera.2011.01.014","article-title":"Immune system to brain signaling: Neuropsychopharmacological implications","volume":"130","author":"Capuron","year":"2011","journal-title":"Pharmacol Ther"},{"key":"R6-20250510","doi-asserted-by":"crossref","first-page":"480739","DOI":"10.1155\/2013\/480739","article-title":"Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain","volume":"2013","author":"Ramesh","year":"2013","journal-title":"Mediators Inflamm"},{"key":"R7-20250510","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2165\/00003495-200565110-00004","article-title":"Immunological aetiology of major psychiatric disorders: Evidence and therapeutic implications","volume":"65","author":"Sperner-Unterweger","year":"2005","journal-title":"Drugs"},{"key":"R8-20250510","first-page":"1","article-title":"Cancer immunotherapy","volume":"26","author":"Dillman","year":"2011","journal-title":"Cancer Biother Radiopharm"},{"key":"R9-20250510","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.critrevonc.2018.08.001","article-title":"A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin","volume":"130","author":"Kattan","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"R10-20250510","first-page":"747","article-title":"Immunotherapy Through the Years","volume":"8","author":"Eno","year":"2017","journal-title":"J Adv Pract Oncol"},{"key":"R11-20250510","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nm0303-269","article-title":"Immunotherapy: Past, present and future","volume":"9","author":"Waldmann","year":"2003","journal-title":"Nat Med"},{"key":"R12-20250510","doi-asserted-by":"crossref","first-page":"1756284819884196","DOI":"10.1177\/1756284819884196","article-title":"Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management","volume":"12","author":"Shivaji","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"R13-20250510","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","article-title":"Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients","volume":"5","author":"De Velasco","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"R14-20250510","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.coph.2016.06.008","article-title":"Psychological side effects of immune therapies: Symptoms and pathomechanism","volume":"29","author":"Kovacs","year":"2016","journal-title":"Curr Opin Pharmacol"},{"key":"R15-20250510","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s001050050976","article-title":"Psychiatric side effects during adjuvant therapy with interferon-alphain patients with malignant melanoma. Clinical evaluation as well as diagnostic and therapeutic possibilities","volume":"50","author":"Sch\u00e4fer","year":"1999","journal-title":"Hautarzt"},{"key":"R16-20250510","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R17-20250510","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R18-20250510","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R19-20250510","doi-asserted-by":"crossref","first-page":"929","DOI":"10.2217\/imt-2017-0056","article-title":"CNS side effects of immune checkpoint inhibitors: Preclinical models, genetics and multimodality therapy","volume":"9","author":"McGinnis","year":"2017","journal-title":"Immunotherapy"},{"key":"R20-20250510","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.psychres.2013.07.001","article-title":"The Brief Psychiatric Rating Scale (version 4.0) factorial structure and its sensitivity in the treatment of outpatients with unipolar depression","volume":"210","author":"Zanello","year":"2013","journal-title":"Psychiatry Res"},{"key":"R21-20250510","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"R22-20250510","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12955-018-1025-5","article-title":"Rasch analysis of the Herth hope index in cancer patients","volume":"16","author":"Rust\u00f8en","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"R23-20250510","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1365-2648.1992.tb01843.x","article-title":"Abbreviated instrument to measure hope: Development and psychometric evaluation","volume":"17","author":"Herth","year":"1992","journal-title":"J Adv Nurs"},{"key":"R24-20250510","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.0283-9318.2003.00247.x","article-title":"The Swedish version of Herth hope index \u2013 An instrument for palliative care","volume":"17","author":"Benzein","year":"2003","journal-title":"Scand J Caring Sci"},{"key":"R27-20250510","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"R28-20250510","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1136\/jech.2005.033076","article-title":"Is perceived nervousness and anxiety a predictor of premature mortality and severe morbidity? A longitudinal follow up of the Swedish survey of living conditions","volume":"59","author":"Ringb\u00e4ck Weitoft","year":"2005","journal-title":"J Epidemiol Community Health"},{"key":"R29-20250510","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/IJGM.S4894","article-title":"Perceived nervousness and moodiness associated with increased CVD but not cancer morbidity in pre-and postmenopausal women. Observations from the Population Study of Women in Gothenburg, Sweden","volume":"2","author":"Hange","year":"2009","journal-title":"Int J Gen Med"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1088_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:25Z","timestamp":1787067505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1088_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1088_20","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2020-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}